1. Home
  2. QNBC vs TRDA Comparison

QNBC vs TRDA Comparison

Compare QNBC & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo QNB Corp. Common Stock

QNBC

QNB Corp. Common Stock

N/A

Current Price

$46.12

Market Cap

281.3M

Sector

Finance

ML Signal

N/A

TRDA

Entrada Therapeutics Inc.

SELL

Current Price

$4.20

Market Cap

275.3M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
QNBC
TRDA
Founded
1877
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
281.3M
275.3M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
QNBC
TRDA
Price
$46.12
$4.20
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
★ $19.00
AVG Volume (30 Days)
18.7K
★ 290.0K
Earning Date
10-23-2026
11-05-2026
Dividend Yield
★ 3.39%
N/A
EPS Growth
★ 21.15
N/A
EPS
★ 1.32
N/A
Revenue
N/A
★ $25,421,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$87.90
P/E Ratio
$34.89
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$44.75
$4.83
52 Week High
$46.60
$16.45

Technical Indicators

Market Signals
Indicator
QNBC
TRDA
Relative Strength Index (RSI) 58.88 22.26
Support Level $45.00 N/A
Resistance Level $46.60 $7.89
Average True Range (ATR) 0.47 0.38
MACD 0.06 -0.12
Stochastic Oscillator 65.63 1.34

Price Performance

Historical Comparison
QNBC
TRDA

About QNBC QNB Corp. Common Stock

QNB Corp is a bank holding company based in the United States. It operates through its wholly-owned subsidiary, which engages in the general commercial banking business and offers a full range of banking services to its customers. Its business activities involve attracting deposits and using funds in making commercial loans, residential mortgage loans, consumer loans, and purchasing investment securities. The loan portfolio includes commercial loans, such as commercial and industrial, construction, and loans secured by commercial real estate and residential real estate, and retail loans, including home equity loans and lines, and consumer loans. It generates revenue from net interest income.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: